A Phase II Trial of Revlimid, as Consolidation Treatment of Residual Disease in Patients With Chronic Lymphocytic Leukemia (CLL)
Latest Information Update: 07 Nov 2021
At a glance
- Drugs Lenalidomide (Primary)
- Indications Chronic lymphocytic leukaemia
- Focus Therapeutic Use
- 01 Oct 2014 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov record.
- 22 May 2012 New trial record